



## MESSAGE FROM LEADERSHIP

Dear friends and family of the McCance Center,

We hope this newsletter finds you relishing the joys of summer, and embracing the rest and revitalization the season brings.

Exciting news! We kicked off the season by hosting a milestone summit with leaders and their teams from the McKnight Brain Institute at the University of Alabama, the newly-launched Center for Mind and Brain Health at Yale School of Medicine, and the Center for Vascular Brain Health at the University of Toronto. We devoted two days to rigorously aligning our research and clinical innovation programs so that we can work together to reduce the incidence of dementia, stroke and depression by at least 10% by 2033. Together, we'll advance prevention, treatment, and overall brain health for all.



In recent months we've also published breakthrough research on sleep, COVID-19, and more. We anticipate updates on our Brain Care Score validation and clinical trial launches this fall.


We are keeping our eyes on all the exciting advancements in the field. In our Center highlights you'll find Dr. Rudy Tanzi's expert insights on the headline-making news about the FDA-approved drug, Leqembi.

With excitement,

*Jonathan Rosand, MD, MSc, Managing Co-Director*  
*Rudy Tanzi, PhD, Co-Director*  
*Greg Fricchione, MD, Co-Director*

---

## McCance Highlights



### [With Leqembi approved, what's next?](#)

**Dr. Rudy Tanzi** discusses the groundbreaking Alzheimer's drug, Leqembi. He delves into the challenges surrounding drug intervention for Alzheimer's and highlights the promising opportunities that lie ahead in the field.


[+ READ MORE](#)



### [Study Reveals Breakthrough 'Sleep Cognitive Indices'](#)

New McCance research introduces "sleep cognitive indices" (SCIs). Unlike traditional biomarkers, SCIs delve deep into cognitive processes. This is an evolution in neurocognitive health assessment!

[+ READ MORE](#)



### [COVID-19 impact on vulnerable communities](#)

COVID-19 lockdown hit vulnerable minority older adults hard. A study led by McCance Clinical Director, **Zeina Chemali, MD, MPH**, studied the impact. Results highlight health and socioeconomic issues needing population-based policy solutions.

[+ READ MORE](#)

## [In the News: Dr. Rudy Tanzi discusses Leqembi on NPR and explores the science of happiness at the World Medical Innovation Forum](#)



### [FDA-approved Alzheimer's drug is 'just the beginning,' says MGH neurologist](#)

While Leqembi has been proven to slow cognitive decline, it is only approved for use in patients with early stages of Alzheimer's.


[Read More](#)



### [The Risks and Benefits of Leqembi, the Newest Alzheimer's Drug, Explained - Consumer Reports](#)

The FDA granted Leqembi full approval on July 6. Here's what to know about who it is for and how it may help.

[Read More](#)



### [Exploring the Science of Happiness: How to Lead a Happier Life](#)

Speakers at the 2023 WMIF discuss a longitudinal study exploring the science of happiness and examining how to lead a happier life.

[Read More](#)



McCANCE

# Brain Care Score™

## Did you know?

- ✓ 40% of dementias can be delayed or prevented
- ✓ 50% of strokes are preventable
- ✓ 38% of major depressive episodes can be prevented

Track your Brain Care Score today.

Follow us on social media and visit our website to get the latest news on our clinical programs and research initiatives.



If you would like to learn more about how you can support the McCance Center for Brain Health, please contact Bridget Flynn at [bflynn6@mgh.harvard.edu](mailto:bflynn6@mgh.harvard.edu), 508-961-8093, or [link here](#).

Massachusetts General Hospital | 399 Revolution Drive, Somerville, MA 02145

[Unsubscribe emccarthy15@partners.org](mailto:emccarthy15@partners.org)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by [bcnunley@mgh.harvard.edu](mailto:bcnunley@mgh.harvard.edu) powered by



Try email marketing for free today!